| Offering Information |
| Expected Date | WITHDRAWN |
| Proposed Exchange/Ticker |
Nasdaq: TVAX |
| Security Type |
Common Stock |
| Lead Underwriter |
Roth Capital Partners Inc |
| Days In Registration |
192 |
| Date Filed |
7-Nov-2011 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2012) |
| Industry |
Manufacturing |
| Business Description |
TVAX Biomedical Inc, located in Lenexa, Kansas, is a biotechnology company focused on the development of targeted cell-based immunotherapies for the treatment of cancer. It uses two cell-based technologies: cancer cell vaccination and the activation and infusion of killer T cells to treat cancer. It was incorporated on July 14, 2011. |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
8.15M |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
- |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
- |
| File Amount |
- |
| File Price Range |
- - - |
| File Mid Price |
- |
|
